Crospon Unveils EndoFLIP Product at 12th World Congress of Endoscopic Surgery

Crospon, a medical device developer based in Galway, Ireland, has today launched its EndoFLIP® http://www.endoflip.com/ product in the U.S. market at the 12th World Congress of Endoscopic Surgery in National Harbor, Washington DC.

The EndoFLIP® product which received FDA clearance in December 2009 is the first product of its kind, which allows a bariatric surgeon to measure and set a consistent gastric band stoma size during surgery.

Crospon develops leading edge minimally invasive medical devices for monitoring, diagnosis and therapy in the gastroenterology area. As part of the World Congress, Crospon also presented, the results of a pilot clinical study which assesses the optimum stoma size for a well adjusted gastric band will be presented.

Speaking at the Congress, Larry Fulton, VP Sales for the Americas, Crospon said, “We are pleased to be launching EndoFLIP® to the U.S. market, following on from its successful release in Europe last year. Gastric banding is the fastest growing class of bariatric surgery in the U.S., and we believe that EndoFLIP® can bring a new science to gastric band adjustment.”

To date, all the key bariatric surgery clinical investigations for EndoFLIP® have taken place at the Speciality Surgery Center of Fort Worth, TX, a center of the American Institute of Gastric Banding (AIGB), the largest gastric band placement institute in the world, under the direction of Principal Investigator Dr. Robert G. Snow.